+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oligonucleotide Therapy Market Report 2025

  • PDF Icon

    Report

  • 250 Pages
  • March 2025
  • Region: Global
  • The Business Research Company
  • ID: 5733854
The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.55 billion in 2024 to $6.18 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally - lung, prostate, bowel, and female breast cancer - constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.6 million) was allocated to assist in expanding life sciences manufacturing in the UK.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

The oligonucleotide therapy market research report is one of a series of new reports that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Oligonucleotide Therapy Market Characteristics3. Oligonucleotide Therapy Market Trends and Strategies4. Oligonucleotide Therapy Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market
5. Global Oligonucleotide Therapy Growth Analysis and Strategic Analysis Framework
5.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Oligonucleotide Therapy Market Growth Rate Analysis
5.4. Global Oligonucleotide Therapy Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Oligonucleotide Therapy Total Addressable Market (TAM)
6. Oligonucleotide Therapy Market Segmentation
6.1. Global Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antisense Oligonucleotide
  • Aptamer
  • Other Types
6.2. Global Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other End-User
6.3. Global Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Research Institutes
6.4. Global Oligonucleotide Therapy Market, Sub-Segmentation of Antisense Oligonucleotide, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • RNA-Targeted Antisense Oligonucleotides
  • DNA-Targeted Antisense Oligonucleotides
  • Chemically Modified Antisense Oligonucleotides
6.5. Global Oligonucleotide Therapy Market, Sub-Segmentation of Aptamer, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA Aptamers
  • RNA Aptamers
  • Small Molecule Aptamers
6.6. Global Oligonucleotide Therapy Market, Sub-Segmentation of Other Types, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • SiRNA (Small Interfering RNA)
  • MiRNA (Micro RNA)
  • DNAzyme and Ribozymes
  • Synthetic Oligonucleotides For Gene Editing
7. Oligonucleotide Therapy Market Regional and Country Analysis
7.1. Global Oligonucleotide Therapy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oligonucleotide Therapy Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Oligonucleotide Therapy Market
8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Oligonucleotide Therapy Market
9.1. China Oligonucleotide Therapy Market Overview
9.2. China Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Oligonucleotide Therapy Market
10.1. India Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Oligonucleotide Therapy Market
11.1. Japan Oligonucleotide Therapy Market Overview
11.2. Japan Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Oligonucleotide Therapy Market
12.1. Australia Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Oligonucleotide Therapy Market
13.1. Indonesia Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Oligonucleotide Therapy Market
14.1. South Korea Oligonucleotide Therapy Market Overview
14.2. South Korea Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Oligonucleotide Therapy Market
15.1. Western Europe Oligonucleotide Therapy Market Overview
15.2. Western Europe Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Oligonucleotide Therapy Market
16.1. UK Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Oligonucleotide Therapy Market
17.1. Germany Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Oligonucleotide Therapy Market
18.1. France Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Oligonucleotide Therapy Market
19.1. Italy Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Oligonucleotide Therapy Market
20.1. Spain Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Oligonucleotide Therapy Market
21.1. Eastern Europe Oligonucleotide Therapy Market Overview
21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Oligonucleotide Therapy Market
22.1. Russia Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Oligonucleotide Therapy Market
23.1. North America Oligonucleotide Therapy Market Overview
23.2. North America Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Oligonucleotide Therapy Market
24.1. USA Oligonucleotide Therapy Market Overview
24.2. USA Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Oligonucleotide Therapy Market
25.1. Canada Oligonucleotide Therapy Market Overview
25.2. Canada Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Oligonucleotide Therapy Market
26.1. South America Oligonucleotide Therapy Market Overview
26.2. South America Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Oligonucleotide Therapy Market
27.1. Brazil Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Oligonucleotide Therapy Market
28.1. Middle East Oligonucleotide Therapy Market Overview
28.2. Middle East Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Oligonucleotide Therapy Market
29.1. Africa Oligonucleotide Therapy Market Overview
29.2. Africa Oligonucleotide Therapy Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oligonucleotide Therapy Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oligonucleotide Therapy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Oligonucleotide Therapy Market Competitive Landscape and Company Profiles
30.1. Oligonucleotide Therapy Market Competitive Landscape
30.2. Oligonucleotide Therapy Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
31. Oligonucleotide Therapy Market Other Major and Innovative Companies
31.1. Moderna Inc.
31.2. Biogen Inc.
31.3. Jazz Pharmaceuticals plc
31.4. QIAGEN Company
31.5. Alnylam Pharmaceuticals Inc.
31.6. Sarepta Therapeutics Inc.
31.7. Ionis Pharmaceuticals Inc.
31.8. Akcea Therapeutics Inc.
31.9. Arrowhead Pharmaceuticals Inc.
31.10. Dicerna Pharmaceuticals Inc.
31.11. SomaGenics Inc.
31.12. Wave Life Sciences Ltd.
31.13. Exicure Inc.
31.14. Avidity Biosciences Inc.
31.15. Miragen Therapeutics Inc.
32. Global Oligonucleotide Therapy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Oligonucleotide Therapy Market34. Recent Developments in the Oligonucleotide Therapy Market
35. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies
35.1 Oligonucleotide Therapy Market in 2029 - Countries Offering Most New Opportunities
35.2 Oligonucleotide Therapy Market in 2029 - Segments Offering Most New Opportunities
35.3 Oligonucleotide Therapy Market in 2029 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Oligonucleotide Therapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for oligonucleotide therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
3) By End User: Hospitals; Research Institutes

Subsegments:

1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
3) By Other Types: SiRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme and Ribozymes; Synthetic Oligonucleotides For Gene Editing

Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; BioNTech SE

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Pfizer Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Gilead Sciences Inc.
  • BioNTech SE
  • Moderna Inc.
  • Biogen Inc.
  • Jazz Pharmaceuticals plc
  • QIAGEN Company
  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • Akcea Therapeutics Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Dicerna Pharmaceuticals Inc.
  • SomaGenics Inc.
  • Wave Life Sciences Ltd.
  • Exicure Inc.
  • Avidity Biosciences Inc.
  • Miragen Therapeutics Inc.
  • ProQR Therapeutics NV
  • Regulus Therapeutics Inc.
  • Kastle Therapeutics LLC
  • Santaris Pharma A/S
  • InteRNA Technologies B.V.
  • Dynacure S.A.
  • Arcturus Therapeutics Holdings Inc.
  • Intellia Therapeutics Inc.
  • Regeneron Pharmaceuticals Inc.
  • Editas Medicine Inc.
  • Evox Therapeutics Ltd.
  • PepGen Ltd.

Table Information